Cargando…
Fc-engineered antibody therapeutics with improved efficacy against COVID-19
Monoclonal antibodies (mAbs) with neutralizing activity against SARS-CoV-2 have demonstrated clinical benefit in cases of mild to moderate SARS-CoV-2 infection, substantially reducing the risk for hospitalization and severe disease(1–4). Treatment generally requires the administration of high doses...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Journal Experts
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168397/ https://www.ncbi.nlm.nih.gov/pubmed/34075373 http://dx.doi.org/10.21203/rs.3.rs-555612/v1 |